Northwestern Medicine investigators have shed new light on how white blood cells in the retina function during inflammation and possibly during retinal vascular diseases with inflammatory components like diabetic retinopathy, according to a study recently published in the Journal of Clinical Investigation.
A combination therapy improved progression-free survival in patients with metastatic castration-resistant prostate cancer with genetic mutations compared to either therapy alone or sequentially, according to results from a Northwestern Medicine-led clinical trial.
Northwestern Medicine investigators have identified distinct T-cell responses associated with patient outcomes in unvaccinated individuals with severe SARS-CoV-2 pneumonia, according to findings published in Nature Immunology.
A new $12 million National Institutes of Health grant led by Northwestern Medicine scientists in collaboration with other institutions will fund studies to identify mechanisms that determine how lung neutrophils drive tissue injury, inflammation and repair in patients with severe pneumonia, lung transplantation and asthma.
A new therapeutic strategy developed by Northwestern investigators activated the gene expression necessary to regenerate cartilage growth within just four hours, according to findings from a recent study.
Northwestern Medicine scientists have uncovered molecular mechanisms underlying lymphatic valve development, a discovery which could prove useful in treating lymphedema, according to a study published in The Journal of Clinical Investigation.
CAR T-cell therapy is an effective treatment for aggressive subtypes of follicular lymphoma, according to a clinical trial published in Nature Medicine.
Subcutaneous delivery of an anti-TNF inhibitor therapy improved remission rates compared to placebo in patients with moderate-to-severe Crohn’s disease and ulcerative colitis who previously completed intravenous anti-TNF therapy, according to clinical trial results published in the journal Gastroenterology.
Patients with immunotherapy-resistant bladder cancer who received a novel combination treatment demonstrated improved response to treatment, according to a recent study published in Nature Medicine.
Multilevel care interventions improved clinician–documented advanced care planning compared with a clinician-level intervention alone for patients with genitourinary cancer, according to recent findings published in JAMA Oncology.
